India, Aug. 25 -- Zymeworks Inc. (ZYME), a biotechnology company, announced on Tuesday receipt of approval from the U.S. Food and Drug Administration (FDA) for Ziihera in two combination regimens for treating HER2+ gastroesophageal adenocarcinoma. The drug is currently licensed to Jazz Pharmaceuticals (JAZZ).
Gastroesophageal adenocarcinoma (GEA) is the fifth most common cancer type worldwide, and includes malignancies of the stomach, gastroesophageal junction, and the esophagus. Patients with metastatic GEA have a survival rate of less than 10% at five years after diagnosis. About 20% test positive for HER2+ mutations, and face high morbidity and mortality rates alongside dwindling alternative treatments.
Ziihera (zanidatamab-hrii) is an...